Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Guardant Health, Inc. is one of them.

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, specializes in blood-based cancer diagnostics, with its flagship Shield test for colorectal cancer (CRC) using AI-driven liquid biopsy technology.

In September 2025, GH unveiled Shield V2, an upgraded version of its CRC test with improved sensitivity (84%) and specificity (90%), enhancing early cancer detection and potential clinical adoption. GH is also expanding commercial access through partnerships with LabFlorida and PathGroup, reaching over 250 hospitals and health systems across 25 states.

Financial performance shows strong momentum, with revenue rising 30.9% year-over-year and full-year 2025 guidance raised to $915-$925 million, positioning GH among the best performing stocks in the diagnostics sector. Looking ahead, Guardant Health, Inc. (NASDAQ:GH) plans to launch its Shield multi-cancer blood test in October 2025, aiming to detect multiple cancers early and significantly expand its diagnostic portfolio, tapping a market with an estimated $50 billion annual potential. Strategic moves include adding former U.S. Health and Human Services Secretary Alex Azar to the board to support commercialization and regulatory efforts.

The firm is also actively defending its intellectual property, recently filing a lawsuit against Sophia Genetics in Paris over liquid biopsy technology, reinforcing its competitive position in precision oncology.

While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.